JP2004525912A - モノアミン取込の阻害剤 - Google Patents

モノアミン取込の阻害剤 Download PDF

Info

Publication number
JP2004525912A
JP2004525912A JP2002569778A JP2002569778A JP2004525912A JP 2004525912 A JP2004525912 A JP 2004525912A JP 2002569778 A JP2002569778 A JP 2002569778A JP 2002569778 A JP2002569778 A JP 2002569778A JP 2004525912 A JP2004525912 A JP 2004525912A
Authority
JP
Japan
Prior art keywords
methyl
phenyl
oxy
aminopropane
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2002569778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525912A5 (enExample
Inventor
エドワード・ルイス・マティウズ
ジョン−マイケル・サワー
ウィリアム・ジョー・ウィーラー
デイビッド・タイワイ・ウォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2004525912(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2004525912A publication Critical patent/JP2004525912A/ja
Publication of JP2004525912A5 publication Critical patent/JP2004525912A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002569778A 2001-03-06 2002-02-20 モノアミン取込の阻害剤 Ceased JP2004525912A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (2)

Publication Number Publication Date
JP2004525912A true JP2004525912A (ja) 2004-08-26
JP2004525912A5 JP2004525912A5 (enExample) 2005-12-22

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002569778A Ceased JP2004525912A (ja) 2001-03-06 2002-02-20 モノアミン取込の阻害剤

Country Status (35)

Country Link
US (2) US20040082666A1 (enExample)
EP (1) EP1379492B1 (enExample)
JP (1) JP2004525912A (enExample)
KR (1) KR20030092012A (enExample)
CN (1) CN1229331C (enExample)
AP (1) AP2003002855A0 (enExample)
AT (2) ATE396170T1 (enExample)
AU (1) AU2002245385B2 (enExample)
BR (1) BR0207716A (enExample)
CA (1) CA2440161A1 (enExample)
CH (1) CH695982A5 (enExample)
CZ (1) CZ20032380A3 (enExample)
DE (1) DE60226715D1 (enExample)
DK (1) DK200301267A (enExample)
EA (1) EA005768B1 (enExample)
EC (1) ECSP034760A (enExample)
EE (1) EE200300419A (enExample)
ES (2) ES2201942B2 (enExample)
FI (1) FI20031191A7 (enExample)
GB (1) GB2389851B (enExample)
HR (1) HRP20030710A2 (enExample)
HU (1) HUP0303341A3 (enExample)
IL (1) IL157779A0 (enExample)
LT (1) LT5143B (enExample)
LU (1) LU91038B1 (enExample)
LV (1) LV13119B (enExample)
NO (1) NO20033921L (enExample)
NZ (1) NZ527431A (enExample)
OA (1) OA12494A (enExample)
PL (1) PL363840A1 (enExample)
SE (1) SE526598C2 (enExample)
SK (1) SK10632003A3 (enExample)
TR (1) TR200705146T1 (enExample)
WO (1) WO2002070457A1 (enExample)
ZA (1) ZA200306882B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法及び組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂
WO2005020976A2 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
WO2000058262A1 (en) 1999-03-29 2000-10-05 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
ATE309196T1 (de) 1999-04-09 2005-11-15 Lilly Co Eli Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
EP1395253A2 (en) * 2000-11-15 2004-03-10 Eli Lilly And Company Treatment of anxiety disorders
CN1229331C (zh) * 2001-03-06 2005-11-30 伊莱利利公司 一元胺吸收的抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法及び組成物

Also Published As

Publication number Publication date
KR20030092012A (ko) 2003-12-03
FI20031191L (fi) 2003-08-25
ATA90422002A (de) 2006-01-15
ATE396170T1 (de) 2008-06-15
US20040082666A1 (en) 2004-04-29
NO20033921D0 (no) 2003-09-04
IL157779A0 (en) 2004-03-28
ES2201942B2 (es) 2004-12-16
SE526598C2 (sv) 2005-10-18
LV13119B (en) 2004-06-20
EE200300419A (et) 2004-02-16
HUP0303341A2 (hu) 2004-01-28
CZ20032380A3 (en) 2004-03-17
AP2003002855A0 (en) 2003-08-20
NO20033921L (no) 2003-11-05
ZA200306882B (en) 2004-12-03
DK200301267A (da) 2003-11-06
EA005768B1 (ru) 2005-06-30
AT414238B (de) 2006-10-15
GB0323169D0 (en) 2003-11-05
US20050209341A1 (en) 2005-09-22
EA200300978A1 (ru) 2004-02-26
HRP20030710A2 (en) 2004-08-31
HUP0303341A3 (en) 2007-03-28
GB2389851B (en) 2005-05-25
NZ527431A (en) 2005-05-27
DE60226715D1 (de) 2008-07-03
EP1379492A1 (en) 2004-01-14
CA2440161A1 (en) 2002-09-12
WO2002070457A1 (en) 2002-09-12
PL363840A1 (pl) 2004-11-29
LT2003075A (en) 2004-03-25
LU91038B1 (fr) 2003-09-11
US7384983B2 (en) 2008-06-10
OA12494A (en) 2006-05-24
ECSP034760A (es) 2003-10-28
CH695982A5 (de) 2006-11-15
WO2002070457A8 (en) 2004-06-03
SE0302361D0 (sv) 2003-09-03
GB2389851A (en) 2003-12-24
SE0302361L (sv) 2003-09-03
TR200705146T1 (tr) 2008-02-21
FI20031191A7 (fi) 2003-08-25
ES2305221T3 (es) 2008-11-01
SK10632003A3 (sk) 2004-06-08
CN1229331C (zh) 2005-11-30
EP1379492B1 (en) 2008-05-21
AU2002245385B2 (en) 2007-01-18
LT5143B (lt) 2004-06-25
CN1494526A (zh) 2004-05-05
ES2201942A1 (es) 2004-03-16
BR0207716A (pt) 2004-03-23

Similar Documents

Publication Publication Date Title
AU2002332289B2 (en) Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
JP2771328B2 (ja) Ｎ―フェニルアルキル置換α―アミノカルボキシアミド誘導体およびその製造方法
EP0288188B1 (en) 1-phenyl-3-naphthalenyloxy-propanamines
US20110288179A1 (en) Bimatoprost crystalline form i
US11905276B2 (en) Bicyclic compound that acts as CRBN protein regulator
US7384983B2 (en) Inhibitor of monoamine uptake
AU2002245385A1 (en) Inhibitor of monoamine uptake
US6214882B1 (en) Benzenesulphonamide derivatives, preparation thereof and therapeutical uses thereof
US7119121B2 (en) 3,3-diphenylpropylamines useful in therapy
US20110097269A1 (en) Phenyloxyaniline derivatives
AU2007201684A1 (en) Inhibitor of monoamine uptake
EP0447727A1 (en) Novel 8-sulfamylmethylene-2-amino tetralins
US7183319B2 (en) Phenylethylamine derivatives and their use in the treatment of melanoma
US20220033376A1 (en) Estrogen receptor antagonist
PT97858A (pt) Metodo para a preparacao de um composto dicloroanilina tendo um substituinte contendo um grupo piridinilo
ES2266416T3 (es) Procedimiento para la preparacion de compuestos 2-(4-alquil-1-piperazinil)-benzaldehido y compuestos de -bencilidenilo por sustitucion nucleofila aromatica de 2-fluorobenzaldehido con 4-alquil-1-piperazina en agua como solvente.
CN101360698A (zh) 具有血清素源性活性和/或去甲肾上腺素能活性的取代芳氧基丙胺

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050218

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070717

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20071127